Heilongjiang ZBD Pharmaceutical Co (603567) Fair Value & Analysis
Healthcare · CN · Market cap 5.6B CNY
Fair value as of: Jul 12, 2026
From 9 valuation models · updated today
Fair value updated Jul 12, 2026 — revised from ¥30.04 to ¥1.19 (−96.0%) since Jun 24, 2026. Share price −26.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥4.28 – ¥13.15 · fair‑value band ¥0.4200 – ¥1.95 · the ¥4.78 price screens above the ¥1.19 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Heilongjiang ZBD Pharmaceutical Co (603567) currently trades at ¥4.78, while our model-based Fair Value estimate is ¥1.19 — implying the stock looks roughly 75.1% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 510M CNY. Revenue declined 61.3% year over year. It earns a return on equity of -22.4%. Net debt stands at 1.3B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥0.4200 (bear case) to ¥1.95 (bull case); at ¥4.78, the current price sits above that range. The share trades about 65% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside — at -75%, 603567 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Heilongjiang ZBD Pharmaceutical Co reported revenue of ¥798M in FY2025 versus ¥4.1B in FY2021, a compound −33.7%/yr. Reported net income was −¥1.4B in FY2025.
Is 603567 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Heilongjiang ZBD Pharmaceutical Co (603567) undervalued?
What is the fair value of 603567?
What is the quality score of 603567?
What is the revenue of Heilongjiang ZBD Pharmaceutical Co (603567)?
What is the net profit margin of 603567?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Heilongjiang ZBD Pharmaceutical Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.